Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HHS Envisions Drug Price Arbitration For Part D

This article was originally published in The Pink Sheet Daily

Executive Summary

Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.

Advertisement

Related Content

Trump Makes A Nasty News Day For Pharma – But What Will It Really Mean?
HHS Raises Profile In Drug Costs Discussion
Pricing, Pediatrics, Pot: 21st Century Cures Amendments
Part D Price Negotiation Provision In House Reform Bill Missing Its Teeth?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS078382

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel